RxDoctor Payments Data

Gregory Whorton, MD

Internal Medicine · Hot Springs, ARNPI 1407857923

Payments from drug & device makers

$4,778in general payments, 2019–2025

Across 306 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$956
  • Pfizer$569
  • Abbott$473
  • Lilly USA, LLC$399
  • Dexcom, Inc.$294
  • Novo Nordisk$229
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,74899%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,778 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$145,814
Medicare patients
365
Services billed
5,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$103,147
OzempicSemaglutide53$82,139
MounjaroTirzepatide43$48,919
XareltoRivaroxaban24$34,813
JanuviaSitagliptin Phosphate24$27,360
JardianceEmpagliflozin22$25,171
MyrbetriqMirabegron43$22,706
FarxigaDapagliflozin Propanediol31$19,933
Breo ElliptaFluticasone/Vilanterol32$18,794
Spiriva RespimatTiotropium Bromide24$17,260
Aimovig AutoinjectorErenumab-Aooe19$13,207
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen394$10,540
CreonLipase/Protease/Amylase15$10,360
LinzessLinaclotide12$10,129
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Dilantin$569$109,412152 claims
Novo NordiskOzempic$229$82,13953 claims
Lilly USA, LLCMounjaro$399$48,91943 claims
Boehringer IngelheimJardiance, Spiriva Respimat$14$42,43146 claims
Johnson & JohnsonXarelto$54$34,81324 claims
MerckJanuvia$32$27,36024 claims
GSKBreo Ellipta, Trelegy Ellipta$62$26,96844 claims
Astellas Pharma US IncMyrbetriq$68$22,70643 claims
AbbVieCreon, Linzess, Synthroid$956$22,26952 claims
AstraZenecaFarxiga$168$19,93331 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$14$4,06511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →